Consensus Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Market Closed - Nyse 21:00:02 17/05/2024 BST 5-day change 1st Jan Change
221.6 USD -1.40% Intraday chart for Charles River Laboratories International, Inc. -2.85% -6.26%

Evolution of the average Target Price on Charles River Laboratories International, Inc.

Price target over the last 5 years

History of analyst recommendation changes

23086ee6b3abcf2f.D7lMofC6JWCvY58Fr6gMxtSMcqhqa2VplbGJSJNl5LM.Xux-ypbORyXjJ_VRzsF8gOC8JsRYOAYQ_dfKCuQjioJFzC_MtMt3E8QPqw~85cab5d39f91bd9615076d9a8e508fb3
TD Cowen Adjusts Price Target on Charles River Laboratories International to $228 From $260 MT
JPMorgan Adjusts Price Target on Charles River Laboratories International to $270 From $280 MT
Jefferies Adjusts Price Target on Charles River Laboratories International to $226 From $235 MT
Evercore ISI Adjusts Price Target on Charles River Laboratories International to $265 From $300 MT
Baird Adjusts Price Target on Charles River Laboratories International to $270 From $282 MT
Zacks Investment Research Adjusts Charles River Laboratories International's Price Target to $259 From $278 MT
Charles River Laboratories Signs Plasmid DNA Manufacturing Deal With Ship of Theseus MT
Deutsche Bank Raises Price Target on Charles River Laboratories to $300 From $275, Keeps Buy Rating MT
Argus Raises Price Target on Charles River Laboratories International to $290 From $200, Maintains Buy Rating MT
Deutsche Bank Raises Charles River Laboratories International Price Target to $275 From $245, Maintains Buy Rating MT
Morgan Stanley Raises Price Target on Charles River Laboratories International to $235 From $205, Keeps Equalweight Rating MT
TD Cowen Adjusts Charles River Laboratories International's PT to $260 From $193, Keeps Market Perform Rating MT
Stephens Adjusts Charles River Laboratories International's PT to $280 From $270, Keeps Overweight Rating MT
Citigroup Adjusts Price Target on Charles River Laboratories International to $250 From $215, Maintains Neutral Rating MT
UBS Adjusts Charles River Laboratories International Price Target to $290 From $270, Maintains Buy Rating MT
JPMorgan Adjusts Price Target on Charles River Laboratories International to $280 From $270, Maintains Overweight Rating MT
Baird Adjusts Price Target on Charles River Laboratories International to $268 From $252, Maintains Outperform Rating MT
Guggenheim Downgrades Charles River Laboratories International to Neutral From Buy MT
Futures climb after Wall St sell-off; rate-cut jitters loom RE
UBS Adjusts Charles River Laboratories International Price Target to $270 From $215, Maintains Buy Rating MT
Citigroup Adjusts Price Target on Charles River Laboratories to $215 From $190, Keeps Neutral Rating MT
Morgan Stanley Cuts Price Target on Charles River Laboratories to $205 From $220, Maintains Equalweight Rating MT
UBS Cuts Charles River Laboratories International Price Target to $215 From $250, Maintains Buy Rating MT
Deutsche Bank Adjusts Charles River Laboratories International Price Target to $215 From $236, Maintains Buy Rating MT
Morgan Stanley Cuts Charles River Laboratories International's Price Target to $220 From $235, Keeps Equalweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
221.6 USD
Average target price
265.6 USD
Spread / Average Target
+19.85%
High Price Target
300 USD
Spread / Highest target
+35.37%
Low Price Target
226 USD
Spread / Lowest Target
+1.98%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Charles River Laboratories International, Inc.

TD Cowen
JPMorgan Chase
Jefferies & Co.
Evercore ISI
Baird
Zacks Investment Research
Deutsche Bank Securities
Argus
Morgan Stanley
Stephens Inc.
Citigroup
UBS
Guggenheim
Wells Fargo Securities
BofA Securities
Credit Suisse
KeyBanc Capital Markets
Truist Securities
Goldman Sachs
J.P. Morgan Chase
  1. Stock Market
  2. Equities
  3. CRL Stock
  4. Consensus Charles River Laboratories International, Inc.